AR121392A1 - Métodos y composiciones para modular los niveles de arginina en células inmunitarias - Google Patents
Métodos y composiciones para modular los niveles de arginina en células inmunitariasInfo
- Publication number
- AR121392A1 AR121392A1 ARP210100448A ARP210100448A AR121392A1 AR 121392 A1 AR121392 A1 AR 121392A1 AR P210100448 A ARP210100448 A AR P210100448A AR P210100448 A ARP210100448 A AR P210100448A AR 121392 A1 AR121392 A1 AR 121392A1
- Authority
- AR
- Argentina
- Prior art keywords
- arginine
- methods
- cells
- car
- compositions
- Prior art date
Links
- 239000004475 Arginine Substances 0.000 title abstract 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 3
- 210000002865 immune cell Anatomy 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 108050005273 Amino acid transporters Proteins 0.000 abstract 1
- 102000034263 Amino acid transporters Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 235000020776 essential amino acid Nutrition 0.000 abstract 1
- 239000003797 essential amino acid Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4637—Other peptides or polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
En el presente documento se divulgan células T y células CAR-T modificadas genéticamente y que tienen una capacidad aumentada para procesar el aminoácido esencial arginina, por ejemplo, mediante la sobreexpresión de transportadores de aminoácidos, particularmente, transportadores de arginina. Dichas células T y células CAR-T modificadas genéticamente pueden mejorar su supervivencia en el microentorno tumoral, generalmente hostil, gracias a su capacidad aumentada para procesar arginina. Los métodos y composiciones descritos en el presente documento se usan para aumentar la cantidad de arginina a disposición de una célula T. Los métodos y composiciones descritos en el presente documento también se usan para aumentar la cantidad de arginina a disposición de una célula CAR-T, proporcionando de esta manera una célula CAR-T que puede ser eficaz en el tratamiento contra tumores sólidos, al sobrevivir en el microentorno tumoral.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062979805P | 2020-02-21 | 2020-02-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121392A1 true AR121392A1 (es) | 2022-06-01 |
Family
ID=77390457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100448A AR121392A1 (es) | 2020-02-21 | 2021-02-22 | Métodos y composiciones para modular los niveles de arginina en células inmunitarias |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230265386A1 (es) |
EP (1) | EP4107254A1 (es) |
JP (1) | JP2023515806A (es) |
KR (1) | KR20220157396A (es) |
CN (1) | CN115427553A (es) |
AR (1) | AR121392A1 (es) |
AU (1) | AU2021223138A1 (es) |
BR (1) | BR112022016571A2 (es) |
CA (1) | CA3171901A1 (es) |
IL (1) | IL295606A (es) |
MX (1) | MX2022010280A (es) |
TW (1) | TW202144569A (es) |
WO (1) | WO2021164753A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202018554D0 (en) * | 2020-11-25 | 2021-01-06 | Cancer Research Tech Ltd | Nucleic acid constructs and cells |
CN114788870B (zh) * | 2022-04-29 | 2023-06-06 | 浙江大学 | 靶向免疫细胞长效补充精氨酸并中和酸环境的组合物及应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201701332D0 (en) * | 2017-01-26 | 2017-03-15 | Tc Biopharm Ltd | Immune cells with modified metabolism and their use thereof |
-
2021
- 2021-02-20 TW TW110105930A patent/TW202144569A/zh unknown
- 2021-02-20 MX MX2022010280A patent/MX2022010280A/es unknown
- 2021-02-20 CA CA3171901A patent/CA3171901A1/en active Pending
- 2021-02-20 JP JP2022550673A patent/JP2023515806A/ja active Pending
- 2021-02-20 US US17/800,958 patent/US20230265386A1/en active Pending
- 2021-02-20 EP EP21757810.3A patent/EP4107254A1/en active Pending
- 2021-02-20 IL IL295606A patent/IL295606A/en unknown
- 2021-02-20 BR BR112022016571A patent/BR112022016571A2/pt unknown
- 2021-02-20 AU AU2021223138A patent/AU2021223138A1/en active Pending
- 2021-02-20 WO PCT/CN2021/077002 patent/WO2021164753A1/en unknown
- 2021-02-20 CN CN202180026648.4A patent/CN115427553A/zh active Pending
- 2021-02-20 KR KR1020227032553A patent/KR20220157396A/ko unknown
- 2021-02-22 AR ARP210100448A patent/AR121392A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021164753A1 (en) | 2021-08-26 |
AU2021223138A1 (en) | 2022-09-29 |
EP4107254A1 (en) | 2022-12-28 |
MX2022010280A (es) | 2022-11-16 |
CN115427553A (zh) | 2022-12-02 |
BR112022016571A2 (pt) | 2022-11-16 |
IL295606A (en) | 2022-10-01 |
KR20220157396A (ko) | 2022-11-29 |
JP2023515806A (ja) | 2023-04-14 |
US20230265386A1 (en) | 2023-08-24 |
TW202144569A (zh) | 2021-12-01 |
CA3171901A1 (en) | 2021-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR121392A1 (es) | Métodos y composiciones para modular los niveles de arginina en células inmunitarias | |
Xu et al. | A metabolism toolbox for CAR T therapy | |
Ye et al. | Oxidative stress, redox regulation and diseases of cellular differentiation | |
Kunwar et al. | Melanin, a promising radioprotector: Mechanisms of actions in a mice model | |
Nishino | Cancer prevention by carotenoids | |
Módis et al. | Regulation of mitochondrial bioenergetic function by hydrogen sulfide. Part II. Pathophysiological and therapeutic aspects | |
AR112328A1 (es) | Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis | |
Gay et al. | Methionine tumor starvation by erythrocyte‐encapsulated methionine gamma‐lyase activity controlled with per os vitamin B6 | |
Juránek et al. | Biological importance of reactive oxygen species in relation to difficulties of treating pathologies involving oxidative stress by exogenous antioxidants | |
BR112013006669A2 (pt) | vetores adenovirais oncolíticos e métodos e usos relacionados aos mesmos | |
BR112013001122A2 (pt) | composições ativas terapêuticas e seu método de uso | |
IN2012DN01964A (es) | ||
Feng et al. | Biogenic polyphosphate nanoparticles from Synechococcus sp. PCC 7002 exhibit intestinal protective potential in human intestinal epithelial cells in vitro and murine small intestine ex vivo | |
Almeida et al. | Carbon monoxide improves neuronal differentiation and yield by increasing the functioning and number of mitochondria | |
ES2690545T3 (es) | Combinación de EPA, DPA y/o DHA con un agente quimioterapéutico | |
Checker et al. | Chemical and biological basis for development of novel radioprotective drugs for cancer therapy | |
Kim et al. | Radioprotective effects of delphinidin on normal human lung cells against proton beam exposure | |
CL2022002150A1 (es) | Moléculas de unión a antígeno anti-cd137 para su administración en el tratamiento contra el cáncer | |
ES2952205T3 (es) | Uso de iones de cobre para potenciar los efectos terapéuticos del arsénico | |
Monti Hughes et al. | Boron neutron capture therapy (BNCT) translational studies in the hamster cheek pouch model of oral cancer at the new “B2” configuration of the RA-6 nuclear reactor | |
Rey et al. | Functional argument for the existence of an avian nitric oxide synthase in muscle mitochondria: Effect of cold acclimation | |
ZA202306735B (en) | Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells | |
Tuji et al. | Ultrastructural assessment of the radioprotective effects of sodium selenite on parotid glands in rats | |
Wong et al. | Urease-induced alkalinization of extracellular pH and its antitumor activity in human breast and lung cancers. | |
Abdollahi | Beneficial effects of cellular autofluorescence following ionization radiation: hypothetical approaches for radiation protection and enhancing radiotherapy effectiveness |